<DOC>
	<DOC>NCT00554216</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of two doses of VI-0521 compared to placebo in treatment of obesity in an adult population with BMI ≥ 35.</brief_summary>
	<brief_title>Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<mesh_term>Phentermine</mesh_term>
	<criteria>Body mass index (BMI) ≥ 35 kg/m2 Informed consent 70 years of age or less Triglyceride level ≤ 200 mg/dL with treatment of 0 or 1 medications Blood pressure of ≤ 140/90 mmHg with treatment of 02 medications for hypertension Fasting blood glucose level of ≤ 110 mg/dL Stroke/myocardial infarction (MI)/unstable cardiovascular disease within 6 months Clinically significant renal, hepatic or psychiatric disease Unstable thyroid disease or replacement therapy Nephrolithiasis Obesity of known genetic or endocrine origin Participation in a formal weight loss program or lifestyle intervention History of glaucoma or intraocular pressure Pregnancy or breastfeeding Alcohol abuse Smoking cessation within previous 3 months or plans to quit smoking during study Eating disorders Cholelithiasis within past 6 months Excluded medications Type 2 diabetes Previous bariatric surgery History of bipolar disorder or psychosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Obesity, morbid obesity</keyword>
</DOC>